Bile acids regulate cardiovascular function

Clinical and Translational Science

Volumn 4, Issue 3, 2011, Pages 210-218

  Khurana, Sandeep ^a   Raufman, Jean Pierre ^a   Pallone, Thomas L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Arteries; Bile acids; Cardiomyocyte; Cirrhosis; Endothelium; Potassium channels; Receptors; Vascular tone

Indexed keywords

ACETYLCHOLINE; BILE ACID; CALCIUM ACTIVATED POTASSIUM CHANNEL; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CHOLIC ACID; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; LITHOCHOLIC ACID; MUSCARINIC RECEPTOR; NITRIC OXIDE; PREGNANE X RECEPTOR; RETINOIC ACID RECEPTOR; TGR5 RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BILE ACID METABOLISM; BLOOD VESSEL TONE; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR FUNCTION; CELL TYPE; CHEMICAL STRUCTURE; CHOLESTEROL METABOLISM; CONCENTRATION (PARAMETERS); ENDOTHELIUM; ENDOTHELIUM CELL; GRAFT REJECTION; HEART CONTRACTION; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART RATE; HEART VENTRICLE; HEPATIC SINUSOIDAL ENDOTHELIAL CELL; HUMAN; HYDROXYLATION; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER FAILURE; MEMBRANE TRANSPORT; MESENTERIC ARTERY; MOLECULAR INTERACTION; NONHUMAN; OBSTRUCTIVE JAUNDICE; POTASSIUM CURRENT; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SINUS NODE; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION;

ANIMALS; BILE ACIDS AND SALTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL MEMBRANE; HEART RATE; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 79959758214     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00272.x     Document Type: Review

References (94)

1. Muller M, Jansen, PLM. Mechanisms of bile secretion. In: Zakim D, Boyer T, editors. Hepatology: A Textbook of Liver Disease, Vol 1, 4th ed. Philadelphia, PA: Saunders Publishing; 2003: 271-290.
2. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009; 32(Suppl2): S237-S245.
3. Vallim TQ, Edwards PA. Bile acids have the gall to function as hormones. Cell Metab. 2009; 10(3): 162-164.
4. Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S, Makino I. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology. 1984; 86(3): 514-520.
5. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut. 2008; 57(9): 1300-1314.
6. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004; 40(2): 467-474.
7. Zecca E, De Luca D, Marras M, Caruso A, Bernardini T, Romagnoli C. Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome. Pediatrics. 2006; 117(5): 1669-1672.
8. Haslewood GA. Bile salt evolution. J Lipid Res. 1967; 8(6): 535-550.
9. Hofmann AF, Sjovall J, Kurz G, Radominska A, Schteingart CD, Tint GS, Vlahcevic ZR, Setchell KD. A proposed nomenclature for bile acids. J Lipid Res. 1992; 33(4): 599-604.
10. Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am J Physiol Gastrointest Liver Physiol. 2003; 284(4): G551-G557.
11. Colpaert CG, Vandenbroucke MP, Andries LJ, Van Marck EA, Brutsaert DL. Role of endocardial endothelium in the positive inotropic effect of cholic acid in isolated myocardium. J Cardiovasc Pharmacol. 1992; 20(Suppl12): S179-S182.
12. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009; 50(12): 2340-2357.
13. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007; 24(10): 1803-1823.
14. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999; 284(5418): 1365-1368.
15. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterström RH, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998; 92(1): 73-82.
16. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998; 95(21): 12208-12213.
17. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res. 2002; 43(3): 359-364.
18. Mukherjee S, Mani S. Orphan nuclear receptors as targets for drug development. Pharm Res. 2010; 27(8): 1439-1468.
19. Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res.c2008; 18(11): 1087-1095.
20. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A. 2004; 101(10): 3668-3673.
21. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem. 2000; 275(14): 10638-10647.
22. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19(8): 1509-1519.
23. Choi M, Yamamoto K, Itoh T, Makishima M, Mangelsdorf DJ, Moras D, DeLuca HF, Yamada S. Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning mutational analysis. Chem Biol. 2003; 10(3): 261-270.
24. Adachi R, Shulman AI, Yamamoto K, Shimomura I, Yamada S, Mangelsdorf DJ, Makishima M. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol Endocrinol. 2004; 18(1): 43-52.
25. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001; 98(6): 3369-3374.
26. Frank C, Makkonen H, Dunlop TW, Matilainen M, Vaisanen S, Carlberg C. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J Mol Biol. 2005; 346(2): 505-519.
27. Hagedorn KA, Cooke CL, Falck JR, Mitchell BF, Davidge ST. Regulation of vascular tone during pregnancy: a novel role for the pregnane X receptor. Hypertension. 2007; 49(2): 328-333.
28. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007; 6(9): 721-733.
29. Raufman JP, Chen Y, Cheng K, Compadre C, Compadre L, Zimniak P. Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry. Eur J Pharmacol. 2002; 457(2-3): 77-84.
30. Raufman JP, Chen Y, Zimniak P, Cheng K. Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology. 2002; 65(4): 215-221.
31. Raufman JP, Zimniak P, Bartoszko-Malik A. Lithocholyltaurine interacts with cholinergic receptors on dispersed chief cells from guinea pig stomach. Am J Physiol. 1998; 274(6 Pt 1): G997-G1004.
32. Khurana S, Yamada M, Wess J, Kennedy RH, Raufman JP. Deoxycholyltaurine-induced vasodilation of rodent aorta is nitric oxide- and muscarinic M(3) receptor-dependent. Eur J Pharmacol. 2005; 517(1-2): 103-110.
33. Sheikh Abdul Kadir SH, Miragoli M, Abu-Hayyeh S, Moshkov AV, Xie Q, Keitel V, Nikolaev VO, Williamson C, Gorelik J. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS One. 5(3): e9689.
34. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11): 9435-9440.
35. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439(7075): 484-489.
36. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Gorg B, Selbach O, Haussinger D, Kubitz R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007; 45(3): 695-704.
37. Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kosters A, Karpen SJ. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology. 2010; 51(6):2097-2107.
38. Yang Y, Murphy TV, Ella SR, Grayson TH, Haddock R, Hwang YT, Braun AP, Peichun G, Korthuis RJ, Davis MJ, et al. Heterogeneity in function of small artery smooth muscle BKCa: involvement of the beta1-subunit. J Physiol. 2009; 587(Pt 12): 3025-3044.
39. Dopico AM, Walsh JV, Jr., Singer JJ. Natural bile acids and synthetic analogues modulate large conductance Ca2+-activated K+ (BKCa) channel activity in smooth muscle cells. J Gen Physiol. 2002; 119(3): 251-273.
40. Mays JK. The active management of intrahepatic cholestasis of pregnancy. Curr Opin Obstet Gynecol. 2010; 22(2): 100-103.
41. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010; 53(1): 179-190.
42. King JH, Stewart HA. Effect of the injection of bile on the circulation. J Exp Med. 1909; 11(5): 673-685.
43. Bogin E, Better O, Harari I. The effect of jaundiced sera and bile salts on cultured beating rat heart cells. Experientia. 1983; 39(11): 1307-1308.
44. Joubert P. Cholic acid and the heart: in vitro studies of the effect on heart rate and myocardial contractility in the rat. Clin Exp Pharmacol Physiol. 1978; 5(1): 9-16.
45. Joubert P. An in vivo investigation of the negative chronotropic effect of cholic acid in the rat. Clin Exp Pharmacol Physiol. 1978; 5(1): 1-8.
46. Binah O, Rubinstein I, Bomzon A, Better OS. Effects of bile acids on ventricular muscle contraction and electrophysiological properties: studies in rat papillary muscle and isolated ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1987; 335(2): 160-165.
47. Kotake H, Itoh T, Watanabe M, Hisatome I, Hasegawa J, Mashiba H. Effect of bile acid on electrophysiological properties of rabbit sino-atrial node in vitro. Br J Pharmacol. 1989; 98(2): 357-360.
48. Gorelik J, Shevchuk A, de Swiet M, Lab M, Korchev Y, Williamson C. Comparison of the arrhythmogenic effects of tauro- and glycoconjugates of cholic acid in an in vitro study of rat cardiomyocytes. Bjog. 2004; 111(8): 867-870.
49. Williamson C, Gorelik J, Eaton BM, Lab M, de Swiet M, Korchev Y. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci (Lond). 2001; 100(4): 363-369.
50. Gorelik J, Harding SE, Shevchuk AI, Koralage D, Lab M, de Swiet M, Korchev Y, Williamson C. Taurocholate induces changes in rat cardiomyocyte contraction and calcium dynamics. Clin Sci (Lond). 2002; 103(2): 191-200.
51. Shah N, Khurana S, Cheng K, Raufman JP. Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol. 2009; 296(2): C221-C232.
52. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology. 2008;149(2): 558-564.
53. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002; 296(5571): 1313-1316.
54. Gorelik J, Patel P, Ng'andwe C, Vodyanoy I, Diakonov I, Lab M, Korchev Y, Williamson C. Genes encoding bile acid, phospholipid and anion transporters are expressed in a human fetal cardiomyocyte culture. Bjog. 2006; 113(5): 552-558.
55. Martinez-Rodenas F, Pereira JA, Jimenez W, Gubern JM, Sitges-Serra A. Circulating bile is the main factor responsible for atrial natriuretic peptide release in experimental obstructive jaundice. Br J Surg. 1998; 85(4): 480-484.
56. Padillo J, Puente J, Gomez M, Dios F, Naranjo A, Vallejo JA, Mino G, Pera C, Sitges-Serra A. Improved cardiac function in patients with obstructive jaundice after internal biliary drainage: hemodynamic and hormonal assessment. Ann Surg. 2001; 234(5): 652-656.
57. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009; 50(9): 1721-1734.
58. Bahrle S, Szabo G, Stiehl A, Theilmann L, Dengler TJ, Zimmermann R, Kubler W. Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection. J Heart Lung Transplant. 1998; 17(6): 592-598.
59. Zhang Q, Nakaki T, Iwami D, Niimi M, Shirasugi N. Induction of regulatory T cells and indefinite survival of fully allogeneic cardiac grafts by ursodeoxycholic acid in mice. Transplantation. 2009; 88(12): 1360-1370.
60. Rajesh KG, Suzuki R, Maeda H, Yamamoto M, Yutong X, Sasaguri S. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway. J Mol Cell Cardiol. 2005; 39(5): 766-776.
61. Lautt WW, Daniels TR. Differential effect of taurocholic acid on hepatic arterial resistance vessels and bile flow. Am J Physiol. 1983; 244(4): G366-G369.
62. Bomzon A, Finberg JP, Tovbin D, Naidu SG, Better OS. Bile salts, hypotension and obstructive jaundice. Clin Sci (Lond). Aug 1984; 67(2): 177-183.
63. Pak JM, Lee SS. Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies. Hepatology. 1993; 18(5): 1175-1181.
64. Pak JM, Adeagbo AS, Triggle CR, Shaffer EA, Lee SS. Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle. Br J Pharmacol. 1994; 112(4): 1209-1215.
65. Ljubuncic P, Said O, Ehrlich Y, Meddings JB, Shaffer EA, Bomzon A. On the in vitro vasoactivity of bile acids. Br J Pharmacol. 2000; 131(3): 387-398.
66. Bukiya AN, Liu J, Toro L, Dopico AM. Beta1 (KCNMB1) subunits mediate lithocholate activation of large-conductance Ca2+-activated K+ channels and dilation in small, resistance-size arteries. Mol Pharmacol. 2007; 72(2): 359-369.
67. Utkan ZN, Utkan T, Sarioglu Y, Gonullu NN. Effects of experimental obstructive jaundice on contractile responses of dog isolated blood vessels: role of endothelium and duration of bile duct ligation. Clin Exp Pharmacol Physiol. 2000; 27(5-6): 339-344.
68. Nakajima T, Okuda Y, Chisaki K, Shin WS, Iwasawa K, Morita T, Matsumoto A, Suzuki JI, Suzuki S, Yamada N, et al. Bile acids increase intracellular Ca(2+) concentration and nitric oxide production in vascular endothelial cells. Br J Pharmacol. 2000; 130(7): 1457-1467.
69. Cheng K, Khurana S, Chen Y, Kennedy RH, Zimniak P, Raufman JP. Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002; 303(1): 29-35.
70. Bukiya AN, Vaithianathan T, Toro L, Dopico AM. The second transmembrane domain of the large conductance, voltage- and calcium-gated potassium channel beta(1) subunit is a lithocholate sensor. FEBS Lett. 2008; 582(5): 673-678.
71. Bukiya AN, Vaithianathan T, Toro L, Dopico AM. Channel beta2-4 subunits fail to substitute for beta1 in sensitizing BK channels to lithocholate. Biochem Biophys Res Commun. 2009; 390(3): 995-1000.
72. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000; 102(6): 731-744.
73. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009; 50(8): 1509-1520.
74. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89(1): 147-191.
75. Li J, Wilson A, Kuruba R, Zhang Q, Gao X, He F, Zhang LM, Pitt BR, Xie W, Li S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 2008; 77(1): 169-177.
76. Kida T, Murata T, Hori M, Ozaki H. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2009; 296(1): H195-H201.
77. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res. 2006; 98(2): 192-199.
78. Zhang Q, He F, Kuruba R, Gao X, Wilson A, Li J, Billiar TR, Pitt BR, Xie W, Li S. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc Res. 2008; 77(3): 560-569.
79. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2606-2611.
80. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol. 2009; 296(2): H272-H281.
81. Miyazaki-Anzai S, Levi M, Kratzer A, Ting TC, Lewis LB, Miyazaki M. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ Res. 2010; 106(12): 1807-1817.
82. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res. 2005; 46(12): 2595-2604.
83. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, Edwards PA. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26(10): 2316-2321.
84. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, Gonzalez FJ. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta. 2006; 1761(12): 1401-1409.
85. Song JG, Cao YF, Sun YM, Ge YH, Xu XW, Yang LQ, Liu ZQ, Song SL, Yu WF. Baroreflex sensitivity is impaired in patients with obstructive jaundice. Anesthesiology. 2009; 111(3): 561-565.
86. Shen FM, Guan YF, Xie HH, Su DF. Arterial baroreflex function determines the survival time in lipopolysaccharide-induced shock in rats. Shock. 2004; 21(6): 556-560.
87. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009; 50(3): 604-620.
88. Das A, Yaqoob U, Mehta D, Shah VH. FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol. 2009; 29(4): 562-570.
89. Soma T, Kaganoi J, Kawabe A, Kondo K, Tsunoda S, Imamura M, Shimada Y. Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: a possible mechanism of angiogenesis in patients with esophageal cancer. Int J Cancer. 2006;119(4): 771-782.
90. Suh H, Jung EJ, Kim TH, Lee HY, Park YH, Kim KW. Anti-angiogenic activity of ursodeoxycholic acid and its derivatives. Cancer Lett. 1997; 113(1-2): 117-122.
91. Woo SJ, Kim JH, Yu HG. Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model. J Ocul Pharmacol Ther. 2010; 26(3): 223-229.
92. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem. 1999; 47(10): 1255-1264.
93. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther. 1998; 285(3): 1260-1265.
94. Ackerman Z, Karmeli F, Amir G, Rachmilewitz D. Renal vasoactive mediator generation in portal hypertensive and bile duct ligated rats. J Hepatol. 1996; 24(4): 478-486.